REtroperitoneal SArcoma Registry: an International Prospective Initiative (NCT03838718)
REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient's Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group
🩺 Plain-English Summary (8th-Grade Level)
Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority. Primary Objectives of this study are: * to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers. * patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM). Secondary Objectives: * to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS; * to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy; * to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR/DM/OS. These may be important biomarkers of disease; * to utilize collected pathological material for research collaborations.
Who can join: Review the eligibility criteria below.
Location: University of Southern California (USC) — Los Angeles, California
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- University of Southern California (USC) — Los Angeles, California
- Mayo Clinic — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute — Emory, Georgia
- Brigham and Women's Hospital/Dana-Farber Cancer Institute — Boston, Massachusetts
- The Ohio State University — Columbus, Ohio
- Peter MacCallum Cancer Center — Melbourne,
- Maisonneuve-Rosemont Hospital / University of Montreal — Montreal,
- The Ottawa Hospital — Ottawa,
- Mount Sinai / Princess Margaret — Toronto,
- Institut Curie — Paris,
- University Medical Center and Medical Faculty Mannheim, University of Heidelberg — Mannheim,
- Ludwig Maximilian University — Munich,
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan,
- Veneto Institute of Oncology — Padova,
- Ospedale Borgo Roma — Verona,
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology — Warsaw,
- Institute of Oncology Ljubljana — Ljubljana,
- Samsung Medical Center — Seoul,
- Hospital Clinico Universitario "Virgen de la Arrixaca" — Murcia,
- University Hospital Birmingham (Queen Elizabeth) — Birmingham,
- Royal Marsden Hospital — London,
📞 Contact the Study Coordinator
Phone: +39022390
Email: alessandro.gronchi@istitutotumori.mi.it
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Retroperitoneal Sarcoma
- Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial) — Houston, Texas
- Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery — Boston, Massachusetts
- Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma — Birmingham, Alabama
- Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma — Chicago, Illinois
- Proton or Photon RT for Retroperitoneal Sarcomas — Chicago, Illinois
Explore by condition: All Retroperitoneal Sarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.